Idiopathic Pulmonary Fibrosis Market Size
| Study Period | 2021- 2029 |
| Market Size (2024) | USD 4.60 Billion |
| Market Size (2029) | USD 6.43 Billion |
| CAGR (2024 - 2029) | 6.95 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Idiopathic Pulmonary Fibrosis Market Analysis
The Idiopathic Pulmonary Fibrosis Market size is estimated at USD 4.60 billion in 2024, and is expected to reach USD 6.43 billion by 2029, growing at a CAGR of 6.95% during the forecast period (2024-2029).
The COVID-19 pandemic has significantly impacted the idiopathic pulmonary fibrosis (IPF) market. While IPF is a chronic lung disease that COVID-19 does not directly cause, it affects various aspects of IPF, such as diagnosis, treatment, and patient care. According to an article published by MDPI in March 2023, SARS-CoV-2 infection caused acute exacerbation of idiopathic pulmonary fibrosis, negatively impacting patients' prognosis. However, there was a high risk of patients developing idiopathic pulmonary fibrosis months after being infected by the COVID-19 infection, leading to increased demand for its treatment modalities.
For instance, according to an article published by Elsevier Public Health Emergency Collection in July 2021, elderly patients who required ICU care and mechanical ventilation were at the highest risk of developing lung fibrosis. Hence, the pandemic has brought greater attention to respiratory health. As a result, there has been an increased awareness and understanding of IPF among the general population and healthcare professionals. This has increased the demand for idiopathic pulmonary fibrosis treatment, which is expected to drive market growth during the forecast period.
The increasing prevalence of idiopathic pulmonary fibrosis, the growing geriatric population, and rising research and development activities in fibrotic diseases are some key factors expected to drive the market's growth during the forecast period. According to an article published by Prescriber, in July 2022, the annual incidence of idiopathic pulmonary fibrosis in Europe was estimated at 0.22 to 7.4 per 100,000 people, and approximately 32,500 people in the United Kingdom had idiopathic pulmonary fibrosis, with a prevalence of about 50 per 100,000 people.
Further, as per the same source, it affects an elderly population and affects men more frequently than women. According to WHO update in October 2022, one in every six individuals globally will be above 60 years by 2030. By that time, the population aged 60 and more will have increased by 1.4 billion. The ageing process is associated with cellular and molecular lung changes, which contribute to the development and progression of idiopathic pulmonary fibrosis. Thus, with the rising geriatric population, the risk of idiopathic pulmonary fibrosis increase, increasing demand for its treatment, thereby driving the market's growth.
The market players are actively involved in product launches, developments, and collaborations to expand their footprint, leading to market growth. For instance, in May 2022, Alembic Pharmaceutical Limited received final approval from the US FDA for pirfenidone tablets in 267 mg and 800 mg doses. Pirfenidone is prescribed for the treatment of idiopathic pulmonary fibrosis.
Therefore, due to the high prevalence of idiopathic pulmonary fibrosis, the growing geriatric population, and the approval of novel drugs, the market studied is expected to during over the forecast period. However, the lack of proper treatment and awareness in developing countries is expected to impede market growth during the forecast period.
Idiopathic Pulmonary Fibrosis Market Trends
Pirfenidone is Expected to Hold a Significant Share in the Global Idiopathic Pulmonary Fibrosis Market Over the Forecast Period
Pirfenidone is an orally administered drug with antifibrotic, anti-inflammatory, and antioxidant effects. This drug is used to slow the disease progression in patients with idiopathic pulmonary fibrosis (IPF). Unlike other therapies, pirfenidone is an oral medication that provides patients convenience and ease of administration. It has a favorable safety profile and is generally well-tolerated, making it a suitable option for long-term treatment.
The rising research and development activities and growing adoption of strategic initiatives such as mergers, acquisitions, partnerships, and investments by key market players associated with the drug pirfenidone allow companies to strengthen their product portfolios and enhance distribution networks, thereby contributing to the studied market growth over the study period. For instance, according to an article published by the Journal of Thoracic Disease, in March 2023, a trial has been registered at the UMIN Clinical Trials Registry for perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation.
Furthermore, per the study article published in the NIH in 2021, pirfenidone provides survival benefits for patients with idiopathic pulmonary fibrosis (IPF). Hence, the rising research and development activities are expected to drive segmental growth. Additionally, the companies are involved in strategic developments such as product launches, acquisitions and collaboration to expand their footprint, which is expected to drive segmental growth. For instance, in June 2022, Accord Healthcare, Inc reported the addition of Pirfenidone to its solid oral products portfolio in the United States. This new drug is therapeutically equivalent to Genentech's Esbriet and is approved to treat idiopathic pulmonary fibrosis (IPF).
Hence, owing to the advantages of pirfenidone over other drug types, ongoing research and development activities, and new product launches, it is expected to hold a significant market share during the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The market for idiopathic pulmonary fibrosis in North America is expected to hold a significant market share owing to the rising burden of patients diagnosed with idiopathic pulmonary fibrosis and the robust healthcare infrastructure to treat idiopathic pulmonary fibrosis. For instance, in January 2022, in the United States, the median age of newly diagnosed patients is 62 years, and 54% are male. According to an article published by Springer Healthcare Communications in January 2023, the adjusted prevalence rates of idiopathic pulmonary fibrosis in North America were 2.40 to 2.98 per 10,000 people. Hence, the high burden of the disease is expected to drive market growth.
Additionally, the strategic initiatives key market players take to strengthen their product portfolios and enhance distribution networks contribute to regional market growth. For instance, in May 2022, PureTech Health plc reported the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. The data support the upcoming registration-enabling studies in which PureTech plans to investigate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF) at the scheduled 550 mg three times daily dose (TID) as well as a dose with a higher total drug exposure than the currently approved dose of pirfenidone to evaluate if higher exposure could translate into improved efficacy. Such initiatives undertaken by market players are anticipated to boost market growth.
Furthermore, product launches, partnerships, and mergers and acquisitions will help the companies expand their product offering and geographical footprints, thereby contributing to the lucrative growth of the market. For instance, in February 2022, Boehringer Ingelheim reported that the US FDA granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for treating idiopathic pulmonary fibrosis (IPF).
Hence, owing to the factors such as the rising burden of idiopathic pulmonary fibrosis and strategic initiative, the market studied is expected to grow over the forecast period in the region.
Idiopathic Pulmonary Fibrosis Industry Overview
The idiopathic pulmonary fibrosis market is moderately competitive in nature, and there are several local and international companies in this market. Some of the key market players in the market are Afferent Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen, Genentech USA Inc., Jubilant Cadista, Merck & Co. Inc., and Prometic Life Sciences.
Idiopathic Pulmonary Fibrosis Market Leaders
-
Cipla Inc.
-
Boehringer Ingelheim International GmbH
-
F. Hoffmann-La Roche Ltd
-
FibroGen, Inc.
-
Horizon Therapeutics plc
*Disclaimer: Major Players sorted in no particular order
Idiopathic Pulmonary Fibrosis Market News
- In January 2023, Daewoong Pharmaceutical signed an agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. Under this agreement, CSP will in-license bersiporocin for idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to USD 336 million, including up to USD 76 million in upfront and development milestone payments and double-digit royalties on net sales.
- In May 2022, Sandoz launched generic pirfenidone, an AB-rated (fully substitutable) equivalent to Genentech's Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF) in the United States.
Idiopathic Pulmonary Fibrosis Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Idiopathic Pulmonary Fibrosis and Growing Geriatric Population
- 4.2.2 Rising Research and Development Activities in Fibrotic Diseases
-
4.3 Market Restraints
- 4.3.1 Unavailability of Proper Treatment and Lack of Awareness in Developing Countries
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Drug Type
- 5.1.1 Nintedanib
- 5.1.2 Pirfenidone
- 5.1.3 Other Drug Types
-
5.2 By Mode of Action
- 5.2.1 Antifibrotic Agents
- 5.2.2 Tyrosine Kinase Inhibitors
- 5.2.3 Other Modes of Action
-
5.3 By End User
- 5.3.1 Hospitals and Clinics
- 5.3.2 Pharmacies
- 5.3.3 Other End Users
-
5.4 By Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 United Therapeutics Corporation
- 6.1.2 Boehringer Ingelheim International GmbH
- 6.1.3 Bristol-Myers Squibb Company
- 6.1.4 Cipla Inc.
- 6.1.5 F. Hoffmann-La Roche Ltd
- 6.1.6 FibroGen Inc.
- 6.1.7 MediciNova Inc.
- 6.1.8 Jubliant Pharma Limited (Jubliant Cadista Limited)
- 6.1.9 Merck & Co. Inc.
- 6.1.10 Horizon Therapeutics Inc.
- 6.1.11 Avalyn Pharma Inc.
- 6.1.12 CS Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityIdiopathic Pulmonary Fibrosis Industry Segmentation
As per the scope of the report, idiopathic pulmonary fibrosis (IPF) refers to a type of lung disease that causes scarring (fibrosis) of the lungs for an unknown reason. As time passes, this scarring gets worse, and it becomes hard to take deep breaths, and the lungs cannot take in enough oxygen. IPF involves the interstitium (the tissue and space around the air sacs of the lungs) and not directly involve the airways or blood vessels.
The idiopathic pulmonary fibrosis market is segmented by drug type, mode of action, end user, and geography. Based on drug type the market is segmented as nintedanib, pirfenidone, and other drug types. Based on mode of action the market is segmented as antifibrotic agents, tyrosine kinase inhibitors, and other modes of action. Based on end users the market is segmented as hospitals and clinics, pharmacies, and other end users. Based on geography the market is segmented by North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD for the above segments.
| By Drug Type | Nintedanib | |
| Pirfenidone | ||
| Other Drug Types | ||
| By Mode of Action | Antifibrotic Agents | |
| Tyrosine Kinase Inhibitors | ||
| Other Modes of Action | ||
| By End User | Hospitals and Clinics | |
| Pharmacies | ||
| Other End Users | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Idiopathic Pulmonary Fibrosis Market Research FAQs
How big is the Idiopathic Pulmonary Fibrosis Market?
The Idiopathic Pulmonary Fibrosis Market size is expected to reach USD 4.60 billion in 2024 and grow at a CAGR of 6.95% to reach USD 6.43 billion by 2029.
What is the current Idiopathic Pulmonary Fibrosis Market size?
In 2024, the Idiopathic Pulmonary Fibrosis Market size is expected to reach USD 4.60 billion.
Who are the key players in Idiopathic Pulmonary Fibrosis Market?
Cipla Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, FibroGen, Inc. and Horizon Therapeutics plc are the major companies operating in the Idiopathic Pulmonary Fibrosis Market.
Which is the fastest growing region in Idiopathic Pulmonary Fibrosis Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Idiopathic Pulmonary Fibrosis Market?
In 2024, the North America accounts for the largest market share in Idiopathic Pulmonary Fibrosis Market.
What years does this Idiopathic Pulmonary Fibrosis Market cover, and what was the market size in 2023?
In 2023, the Idiopathic Pulmonary Fibrosis Market size was estimated at USD 4.28 billion. The report covers the Idiopathic Pulmonary Fibrosis Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Idiopathic Pulmonary Fibrosis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Idiopathic Pulmonary Fibrosis Industry Report
The Idiopathic Pulmonary Fibrosis Market is segmented by drug type, mode of action, end user, and geography. The market size is influenced by various factors including the type of drugs such as nintedanib and pirfenidone. The industry report provides a comprehensive market analysis and industry overview, highlighting the market share and market forecast for the upcoming years. The market growth is driven by the increasing prevalence of idiopathic pulmonary fibrosis and the introduction of new treatment options.
The industry analysis includes detailed insights into the market segmentation, which covers hospitals and clinics, pharmacies, and other end users. The market leaders in this sector are focusing on expanding their market value through strategic initiatives. The report example provides a market review and market outlook, emphasizing the industry trends and market predictions.
The industry reports offer valuable industry information and industry statistics, which are essential for understanding the market dynamics. The market data is crucial for identifying market opportunities and challenges. The report pdf is available for download, providing an in-depth industry research and market forecast.
The growth rate of the idiopathic pulmonary fibrosis market is expected to remain steady, supported by continuous advancements in medical research. The industry size and industry sales are projected to increase, driven by the demand for effective treatment options. The market overview includes a detailed analysis of the market segmentation and market trends.
Research companies play a significant role in providing industry insights and market predictions. The market outlook is positive, with a focus on developing innovative therapies. The industry outlook is promising, with a steady increase in market value. The industry research highlights the key factors influencing the market growth and provides a comprehensive market review.
